Long-term immunological memory in the resistance of rats to transplanted intracerebral 9L gliosarcoma (9LGS) following subcutaneous immunization with 9LGS cells

Journal of Neuro-Oncology

Volumn 46, Issue 3, 2000, Pages 193-203

  Smilowitz, H M ^a   Joel, D D ^b   Slatkin, D N ^a   Micca, P L ^b   Nawrocky, M M ^b   Youngs, K ^b   Tu, W ^a   Coderre, Jeffrey A ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Aging; BNCT; Glioma; Immunological memory; Vaccine

Indexed keywords

TUMOR CELL VACCINE;

AGING; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; GLIOMA CELL; GLIOSARCOMA; IMMUNOLOGICAL MEMORY; NEUTRON CAPTURE THERAPY; NONHUMAN; RAT;

ANIMALS; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; GLIOSARCOMA; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; INJECTIONS, SUBCUTANEOUS; MALE; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0034131515     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006488301412     Document Type: Article

References (51)

1. Coderre, JA: Boron neutron-capture therapy. In: Leibel, SA and Phillips TL (eds) Radiation Oncology. W.B. Saunders Co., Philadelphia, 1998, pp 1263-1277
2. Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolski L, Chanana AD: Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys 40: 829-834, 1998
3. Elowitz MD, Bergland RM, Coderre JA, Joel DD, Chadha M, Chanana AD: Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy. Neurosurgery 42: 463-469, 1998
4. Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, Iwai J, Joel DD, Liu HB, Ma R, Pendzick N, Peress NS, Shady MS, Slatkin DN, Tyson GW, Wielopolski L: Boron neutron capture therapy for glioblastoma multiforme: results from the initial phase I/II dose escalation studies. Neurosurgery 44:1182-1192, 1999
5. Dietrich PY, Walker PR, Saas P, De Tribolet N: Immunobiology of gliomas: new perspectives for therapy. Ann NY Acad sci 824:124-140, 1997
6. Shu S, Plautz GE, Krauss JC, Chang AE: Tumor immunology. JAMA 278: 1972-1981, 1997
7. Peterson DL, Sheridan PJ, Brown Jr WE: Animal models for brain tumors: historical perspectives and future directions. J Neurosurg 80: 865-876, 1994
8. Barth RF: Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neuro-Oncol 36: 91-102, 1998
9. Wechsler W, Kleihves P, Matsumoto S, Zulch KJ, Ivankovic S, Preussman R, Druckrey H: Pathology of experimental neurogenic tumors chemically induced during prenatal and postnatal life. Ann NY Acad Sci 159: 360-408, 1969
10. Aas AT, Brun A, Blennow C, Stromblad S, Salford LG: The RG2 rat glioma model. J Neuro-Oncol 23: 175-183, 1995
11. Schmidek HH, Neilsen SL, Schiller AL, Messer J: Morphological studies of rat brain tumors induced by N-nitrosomethylurea. J Neurosurg 34: 335-340, 1971
12. Benda P, Someda K, Messer J, Sweet WH: Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J Neurosurg 34: 310-323, 1971
13. Joel DD, Fairchild RG, Laissue JA, Saraf SK, Kalef-Ezra JA, Slatkin DN: Boron neutron capture therapy of intracerebral rat gliosarcomas. Proc Natl Acad Sci USA 87: 9808-9812, 1990
14. Blume MR, Wilson CB, Vasquez DA: Immune response to a transplantable intracerebral glioma in rats. Recent Prog Neurolog Surgery 5: 129, 1974
15. Denlinger RH, Axler DA, Koestner A, Liss L: Tumor-specific transplantation immunity to intracerebral challenge with cells from a methylnitrosourea-induced brain tumor. Journal of Medicine 6: 249-259, 1975
16. Morantz RA, Wood GW, Foster M, Clark M, Gollahon K: Macrophages in experimental and human brain tumors. Part 1: studies of the macrophage content of experimental rat brain tumors of varying immunogenicity. J Neurosurg 50: 298-304, 1979
17. Tzeng J-J, Barth RF, Orosz CG, James SM: Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and nonimmunogenic rat brain tumors. Cancer Res 51: 2373-2378, 1991
18. Joel DD, Slatkin DN, Fairchild RG, Micca P, Nawrocky MM: Pharmacokinetics and tissue distribution of the sulfhydryl boranes (monomer and dimer) in glioma-bearing rats. Strahlenther Onkol 165: 167-170, 1989
19. Coderre JA, Makar MS, Micca PL, Nawrocky MM, Liu HB, Joel DD, Slatkin DN, Amols HJ: Derivations of relative biological effectiveness for the high-LET radiations produced during boron neutron capture irradiations of the 9L rat gliosarcoma in vitro and in vivo. Int J Radiat Oncol Biol Phys 27: 1121-1129, 1993
20. Russel DS, Rubinstein LJ: Pathology of tumors of the nervous system. Williams and Wilkins, Baltimore, 5th edn, 1989
21. Lentner C (ed): Geigy Scientific Tables, 8th edn., Vol.2. Geigy, Basle, 1982
22. Foley EJ: Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13: 835-837, 1953
23. Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769-778, 1957
24. Revesz L: Detection of antigenic differences in isologous host-tumor systems by pretreatment with heavily irradiated tumor cells. Cancer Res 20: 443-451, 1960
25. Old LJ, Boyse EA, Clark DA, Carswell E: Antigenic properties of chemically induced tumors. Ann NY Acad Sci 101: 80-106, 1962
26. Geyer SJ, Landay A: Immunogenetic and immunologic aspects of gliosarcoma growth in rats. Lab Invest 49: 436-444, 1983
27. Tracey RS, Wepsic HT, Alaimo J, Morris HP: Growth of transplanted rat tumors following administration of cell-free tumor antigens. Cancer Res 38: 1208-1212, 1978
28. Mackinodan T, Kay MMB: Age influence on the immune system. Adv Immunol 29: 287-294, 1980
29. Wade AW, Szewczuk MR: Aging, idiotype repertoire shifts and compartmentalization of the mucosal-associated lymphoid system. Adv Immunol 36: 143-188, 1984
30. Thoman ML, Weigle WO: The cellular and subcellular basis of immunosenescence. Adv Immunol 46: 221-261, 1989
31. Flood PM, Urban JL, Kripke ML, Schrieber H: Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med 154: 275-290, 1981
32. Fitzgerald PA, Bennett M: Aging of natural and acquired immunity of mice: II. Decreased T cell response to syngeneic tumor cells and parenteral-strain spleen cells. Cancer Invest 1: 139-149, 1983
33. Urban JL, Schrieber H: Rescue of tumor-specific immune response of aged mice in vitro. J Immunol 133: 527-534, 1984
34. Dunn PL, North RJ: Effect of advanced aging on ability of mice to cause regression of an immunogenic lymphoma in response to immunotherapy based on depletion of suppressor T cells. Cancer Immunol Immunother 33: 421-423, 1991
35. Flood PM, Liu X, Alexander R, Schreiber H, Haque S: Loss of resistence to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity. J Immunol 21: 307-316, 1998
36. Tseng SH, Hwang LH, Lin SM: Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J Immunotherapy 20: 334-342, 1997
37. Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC: Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurg 42: 850-857, 1998
38. Fernandez-Cruz E, Halliburton B, Feldman JD: In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J Immunol 123: 1772-1781, 1979
39. Greenberg PD, Cheever MA, Fefer A: Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res 40: 4428-4432, 1980
40. Leclerc J-C, Cantor H: T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo. J Immunol 124: 851-854, 1980
41. Berendt MJ, North RJ: T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151: 69-80, 1980
42. North RJ: The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 35: 89-154, 1984
43. North RJ: Down-regulation of the antitumor immune response. Adv in Cancer Res 45: 1-43, 1985
44. Hodi FS, Dranoff G: Genetically modified tumor cell vaccines. Surg Oncol Clinics N America 7: 471-485, 1998
45. Young HF, Merchant RE, Apuzzo MLJ: Immunocompetence of patients with malignant gliomas. In: Salcman M (ed) Neurobiology of Brain Tumors. Williams and Wilkins, Baltimore, 1991, pp 211-227
46. Grace Jr JT, Perese DM, Metzgar RS, Sasabe T, Holdridge B: Tumor allograft responses in patients with glioblastoma multiforme. J Neurosurg 18: 159-167, 1961
47. Trouillas P, Lapras C: Immunotherapie active des tumeurs cérébrales. A propos de 20 cas. Neurochirurgie 16: 143-170, 1970
48. Febvre H, Maunoury R, Constans JP, Trouillas P: Delayed hypersensitivity reactions in patients bearing malignant brain tumors with human tumor cell lines grown in vitro. Int J Cancer 10: 221-232, 1972
49. Trouillas P: Immunologie et immunotherapie active des tumeurs cerebrales. Rev Neurol 128: 23-38, 1973
50. Mahaley Jr MS, Gillespie GY, Gillespie RP, Watkins PJ, Bigner DD, Wikstrand CJ, MacQueen JM, Sanfilippo F: Immunology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas. J Neurosurg 59: 208-216, 1983
51. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, Becker DP, Bronstein JM: Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90: 1115-1124, 1999